Family Med

Your Article Summary

See Latest Articles

Identification of a novel human cellular HDL biosynthesis defect
European Heart Journal, 06/30/09

Rashid S et al. – Results indicate for the first time in humans that phospholipid and cholesterol efflux are 2 separate and distinct processes in cellular high-density lipoprotein (HDL) biosynthesis and that normal cellular phospholipid efflux is necessary for formation of larger {alpha}-HDL particles. Defective ABCA1 protein regulation results in a defect in phospholipid efflux, treatable with physiological oxysterols, a current therapeutic target that may serve to raise HDL levels in severe HDL deficiencies, pending further study.

• Study of the cellular basis of a novel HDL-deficiency phenotype
• Screen of 54 subjects of French Canadian ancestry with severe HDL deficiency
• Exclusion of pts with mutations in genes currently associated with low HDL (ABCA1, LCAT, APOA-I, and SMPD1)

• Cellular phospholipid efflux impaired in HDL biosynthesis process but cholesterol efflux normal in 2 pts
• On 2-dimensional gel electrophoresis analysis, the 2 impaired phospholipid efflux pts primarily defective in larger {alpha}-HDL subpopulations
• In fibroblasts from affected subjects, oxysterol stimulation resulted in increased ABCA1 protein expression and normalized defective phospholipid efflux defect

Today in Atherosclerosis/Lipids...keeping you current

Receive free subspecialty "5-minute updates" via email

Nutritional supplements and serum lipids: Does anything work
Current Atherosclerosis Reports, 11/16/09

Carbohydrate-restricted diets for obesity and related diseases: An update
Current Atherosclerosis Reports, 11/17/09

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

See All of Atherosclerosis/Lipids